Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102, an investigational therapy intended as a one-time treatment for hypercholesterolaemia.
The single-ascending-dose, open-label trial showed notable reductions in LDL-cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) protein after a single infusion.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It involved 35 participants with heterozygous familial hypercholesterolaemia (HeFH) or premature coronary artery disease (CAD).
A single dose of VERVE-102, administered intravenously, showed dose-dependent mean reductions in circulating PCSK9 ranging from 51% to 88% and corresponding reductions in LDL-C from 9% to 62% across six dose cohorts.
These results have been durable for up to 18 months post-treatment.
VERVE-102 was generally well tolerated, with no treatment-related serious adverse events or dose-limiting toxicities reported.
Adverse events included low-grade infusion reactions and fatigue, but all participants received their full doses, and none withdrew from the trial.
Lilly senior vice-president Sekar Kathiresan said: “20 years ago, genetics showed us that people born with PCSK9 naturally turned off have low LDL-C for life and are remarkably protected from heart attack, yet today’s chronic therapies struggle to deliver this lifelong lowering.
“The Heart-2 results provide early clinical evidence that a single dose of VERVE-102 may mimic the LDL-C lowering effects of PCSK9 cardioprotective variants, potentially transforming cardiovascular care from chronic management to a one-time treatment.”
The US Food and Drug Administration (FDA) has granted fast track designation to VERVE-102 for reducing LDL-C in people with hyperlipidaemia and elevated long-term cardiovascular risk.
Lilly plans to begin Phase II studies of VERVE-102 by this year’s end.
Last month, Eli Lilly’s Jaypirca (pirtobrutinib) succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL).
